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Renal vein thrombosis in idiopathic membranous glomerulopathy and
nephrotic syndrome: Incidence and significance. The point prevalence
and clinical significance of renal vein thrombosis (RVT) was evaluated
in 27 of 33 consecutive nephrotic patients with idiopathic membranous
glomerulopathy. A technique of retrograde venography after the injec-
tion of epinephrine into the main renal artery to decrease renal blood
flow was used. Two patients had histories compatible with a thrombo-
embolic event, and the excretory urogram was not suggestive of RVT in
any patient. RVT was noted in 13 patients; in eight it was bilateral. All
patients with RVT received anticoagulant drugs for a minimum of 1 year
after the study, and no thromboembolic events occurred in this group.
No patient was treated with corticosteroids. Follow-up observation of
an average of 2.5 years has not revealed a significant difference in the
rate of renal function deterioration or change in degree of proteinuria
between patients with and without RVT. Coagulation abnormalities
included elevated platelet counts and plasma fibrinogen levels and
prolonged reptilase and thrombin times. These were noted in all 14
patients studied, six of whom had RVT. In patients experiencing a
nephrotic remission, coagulation abnormalities reverted to normal.
RVT is common in idiopathic membranous glomerulopathy with ne-
phrosis and is associated with few clinical markers. Its influence on
renal function and proteinuria is of questionable significance. Coagula-
tion abnormalities may be a causative factor of RVT in this setting.
Thrombose des veines rénales dans Ia glomerulonephrite extramem-
braneuse idiopathique et le syndrome nephrotique: Incidence et significa-
tion. La prevalence et Ia signification clinique de Ia thrombose des
veines rénales (RVT) ont été évaluées chez 27 sur 33 malades consécu-
tifs néphrotiques avec une glomerulonéphrite extramembraneuse idio-
pathique. Une technique de phlébographie retrograde apres injection
d'adrénaline dans l'artére rénale principale afin de diminuer le flux
sanguin renal a été utilisée. Deux malades avaient des histoires compa-
tibles avec un accident thrombo-embolique, Enais l'urographie n'était
évocatrice de RVT chez aucun malade. Une RVT a été notée chez 13
malades; chez huit elle était bilatérale. Tous les malades ayant une RVT
ont recu des anticoagulants pendant au moms 1 an après l'étude, et
aucun accident thrombo-embolique nest survenu dans ce groupe.
Aucun malade n'a été traité avec des corticostéroides. Le suivi pendant
une moyenne de 2,5 ans n'a pas révélé de difference significative dans la
frequence de détérioration de Ia fonction rénale ou de modification du
degre de protëinurie entre les malades avec ou sans RVT. Les anoma-
lies de Ia coagulation comprenaient une augmentation des plaquettes et
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des concentrations plasmatiques de fibrinogene et un allongement des
temps de reptilase et de thrombine. Ces anomalies ont été notées chez
les 14 malades étudiés, dont six avaient une RVT. Chez les patients
ayant une remission nephrotique, les anomalies de Ia coagulation sont
revenues a Ia normale. La RVT est frequente lors de Ia glomerulonéph-
rite extramembraneuse idiopathique avec néphrose et est associée a peu
de marqueurs cliniques. Son influence sur Ia fonction rénale et Ia
protéinurie est d'importance douteuse. Les anomalies de Ia coagulation
pourraient étre un facteur causal de RVT dans cette condition.
The association of the nephrotic syndrome and thrombosis of
the renal veins has been recognized for more than 100 years [I].
Earlier studies suggested that thrombosis of the renal vein was
the precipitating event for the development of the nephrotic
syndrome and possibly the renal glomerular lesions encoun-
tered. Animal studies, however, in which main renal vein
occlusion was produced experimentally, have failed to demon-
strate the development of heavy proteinuria unless the contra-
lateral normal kidney is removed [21. Similarly, glomerular-
immune deposits or other overt capillary membrane changes
have not been produced with this maneuver [3].
Although sporadic clinical reports have implicated trauma-
induced renal vein thrombosis as a possible cause of the
nephrotic syndrome [4, 5], serial studies [6, 7] have shown that
renal vein thrombosis, when accompanied by heavy protein-
uria, is a complication of the nephrotic syndrome and not the
cause. Renal vein thrombosis has been found in nephrotic
patients with glomerular diseases of the primary type, such as
membranous glomerulopathy [71, nil lesion disease [8], mem-
branoproliferative glomerulonephritis [61, focal glomeruloscle-
rosis [6], and rapidly progressive glomerulonephritis [6], and in
nephrosis associated with systemic diseases, such as lupus
erythematosus [91, diabetes mellitus [10], primary amyloidosis
[11], familial Mediterranean fever with amyloidosis [121, sickle
cell disease [10], sarcoidosis [13], and vasculitis [10].
Coagulation abnormalities, now well recognized in nephrotic
patients [14—16], may be a factor in the genesis of the renal vein
thrombosis, as these abnormalities occur regardless of the type
of renal disease and revert to normal if nephrotic remission is
complete.
Renal vein thrombosis in nephrotic patients has been de-
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scribed most frequently in association with idiopathic membra-
nous glomerulopathy. The incidence of the complication when
associated with this renal lesion, the extent of the thrombosis
within the intrarenal venous system, the influence it exerts on
the course of renal function, and the course of proteinuria, as
well as its significance as a risk factor for other thromboembolic
events, are not established completely. This prospective study
was undertaken in an attempt to provide information pertinent
to these considerations of practical importance.
Methods
Patient selection. Between 1976 and 1979, 33 patients were
seen at the Mayo Clinic for the first time with the diagnosis of
idiopathic membranous glomerulopathy and the nephrotic syn-
drome. The geographical area of distribution and the means by
which they were referred to the Mayo Clinic were similar to
those of the overall patient population seen at this institution.
Most patients were referred by primary physicians for evalua-
tion of proteinuria or edema formation. Four patients were
referred by other nephrologists and, at the request of the
patient, for a second opinion regarding diagnosis and manage-
ment. All patients were seen by members of the Division of
Nephrology and, by common consent of those consultants,
were invited to participate in the study. Twenty-seven patients
accepted. Of the remaining six patients, entrance into the study
was declined either by the patient or by a non-nephrologist
attending physician: Two were more than 75 years old, one had
rheumatic valvular heart disease, and three elected to defer
angiography and did not return. Criteria for the diagnosis of the
nephrotic syndrome included (1) 24-hr urine protein excretion
greater than 3.5 g, as measured by the biuret method, (2) serum
albumin level less than 3.0 g/dl, and (3) free lipids on routine
urinalysis.
Follow-up and treatment. Patients were reassessed periodi-
cally for changes in renal function and degree of proteinuria and
clinical evidence suggestive of thromboembolic events. Patients
found to have renal vein thrombosis were given warfarin for a
minimum of 1 year, and an effort was made to keep the pro-
thrombin time twice the control value. No patient was given
corticosteroids during the period of observation. Follow-up
renal vein angiography was performed in three patients who had
an initial finding of renal vein thrombosis.
Renal morphology. Renal tissue samples were obtained from
all patients by the percutaneous technique using the Franklin
modification of the Vim-Silverman needle. Morphologic criteria
for the diagnosis of membranous glomerulopathy included (1)
diffuse glomerular capillary wall thickening with no local in-
crease in mesangial cells and matrix and no proliferation of
other intracapillary or extracapillary cells on light microscopy,
(2) deposits of immunoglobulins and complement in a character-
istic granular pattern along glomerular capillary walls noted on
immunofluorescent staining, and (3) electron-dense subepithe-
hal and intraglomerular basement membrane deposits noted on
electron microscopy. Renal tissue was available for light and
electron microscopy in all 27 patients and for immunofluores-
cent examination in 25 patients. Techniques of preparation for
renal tissue examination of these three forms of microscopy
have been described previously [17].
The initial morphologic interpretation was made before angi-
ography results were known and without the pathologist's
knowledge of the patient's clinical history. At the termination of
the study, the renal morphologic findings were reviewed by one
of the authors, and again this was done without access to
patient identification or clinical history. The renal morphologic
patterns were subdivided into four stages of membranous
glomerulopathy according to the classification of Ehrenreich
and Churg [18]. Light microscopy evaluation also included
quantitative scoring of glomerular obsolescence, intraluminal
capillary leukocytes presence, tubular degeneration, and inter-
stitial cellular infiltration and fibrosis.
Angiography. All angiographic studies were performed with-
in 7 days after the renal biopsy procedure, with the exception of
studies in four patients in which renal biopsy was performed
elsewhere. In these four patients, there was a maximal interval
of 4 months between the biopsy procedure and the angiographic
study. Renal angiography included selective arterial and venous
injections of contrast material with direct magnification filming.
The renal venous injections were preceded by an injection of 10
mg of epinephrine into the respective renal artery, reducing
arterial flow and allowing enhanced retrograde venous filling.
Angiographic procedures and their initial interpretation were
performed by three radiologists who had no knowledge of any
clinical information except the diagnosis of membranous gb-
merulopathy and the nephrotic syndrome. When the study
ended, the angiograms were reviewed by one radiologist.
Except for the knowledge that all patients satisfied the criteria
for inclusion in the study, that is, membranous glomerulopathy
and the nephrotic syndrome, no other information was made
available to the reviewer.
Laboratory studies. For assessment of renal function, all
patients had a serum creatinine determination initially and at
each subsequent examination. All patients had excretory urog-
raphy before the angiogram study.
Coagulation studies. Fourteen patients had coagulation stud-
ies performed which compose the screening profile used at this
institution for patients with suspected thrombosing tendencies.
These include (1) platelet count, (2) plasma fibrinogen, (3)
prothrombin time, (4) partial plasma thromboplastin time, (5)
activated partial plasma thromboplastin time, (6) antithrombin
III, measured by a radioimmunodiffusion technique [19] and by
a functional method [20], (7) serum fibrin split products, (8)
protamine gel time, (9) reptilase time, and (10) factor VIII
activity.
Definitions. Duration of nephrotic syndrome was defined as
the time from the onset of formation of clinical edema or the
initial quantitation of urine protein in the nephrotic range to the
time of angiography. The follow-up period encompassed the
time from the angiogram study to death, entrance into a dialysis
or transplant program, or the date of the most recent
examination.
Results
Angiographic findings. Of the 27 patients who consented to
enter the study, 18 were men. The age range of the total group
was 22 to 72 years.
Thirteen of the 27 patients studied were initially found to
have renal vein thrombosis. One patient with an initial negative
study died of sepsis 2 months later, and autopsy revealed that
bilateral renal vein thrombosis had developed during the inter-
im. Ten patients had main renal vein involvement (Fig. 1); in
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Fig. 1. Right main renal vein thrombus (incomplete occlusion).
Fig. 2. Bilateral main vein thrombi (incomplete occlusion), with exten-
sion into inferior vena cava (same patient as in Fig. I).
four, the involvement was bilateral (Fig. 2) and in three, there
was extensive venous collateral circulation. In two patients,
one main renal vein was occluded completely. The left main
renal vein was involved in nine of these ten patients and the
right in five. Three patients had intraparenchymal vein throm-
bosis (Fig. 3); in one, it was bilateral, which was later confirmed
in nephrectomy specimens.
A comparison of the second or reviewed angiogram interpre-
tation performed at the close of the study did not reveal
variation from the original interpretation, with one exception — a
quantitative difference in the extent of interparenchymal ve-
nous thrombosis in one patient. Reproducibility of the radiolog-
ic interpretation was believed to be excellent because of the
detail afforded by this particular angiographic technique.
Fig. 3. Right kidney with intrarenal venous thrombi (arrows).
Three patients with bilateral main renal vein thrombosis were
studied again 1 year after the initial evaluation and after
anticoagulation with warfarin had been maintained for the
entire period. All three follow-up studies were interpreted as
normal, an observation also noted by others [21, 22]. One of the
three patients was in complete nephrotic remission with a stable
serum creatinine level. One patient was in partial remission,
and one was still nephrotic at the time of follow-up angiography;
these two patients who were not in complete remission were
experiencing deterioration of renal function.
Complications related to angiography included a pulmonary
embolus in one patient, catheter perforation of the inferior vena
cava with contrast medium extravasation in one, and contrast
medium-induced acute renal failure in one. In all patients,
conservative treatment resulted in an uneventful recovery from
these complications.
Renal morphologic findings. Renal biopsy tissue, initially
interpreted and later reviewed without knowledge of the angio-
graphic findings, showed no significant morphologic quantita-
tive differences between patients with and without renal vein
thrombosis. Specifically, capillary wall leukocyte margination,
interstitial edema or fibrosis, and tubular atrophy were not
suggestive indicators of renal vein thrombosis, as has been
described by others [23]. In addition, with one exception, no
evidence of small renal vein occlusion was seen on light
microscopy, and no significant positive fluorescence for fibrino-
gen was noted in patients with renal vein thrombosis, findings
that have been reported by some investigators [241. The distri-
bution of morphologic staging, as defined by Ehrenreich and
Churg [18], was similar in both groups: Of the 14 patients
without renal vein thrombosis, three were stage I, five were
stage II, and six were stage III; of the 13 patients with vein
thrombosis, two were stage I, three were stage II, and eight
were stage III.
Initial clinical parameters between patients with and those
without renal vein thrombosis were similar (Table I). Two
patients with renal vein thrombosis related a history compatible
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Table 1. Idiopathic membranous glomerulopathy, nephrotic syndrome, and renal vein thrombosis
— 130,000 to 20 to 21
370,000
— 190 to 365 <3 Negative 70 to 130 17 to 30
Patient value/control value.
Follow-up coagulation abnormalities became normal with nephrotic remission.
with pulmonary embolus. One patient without renal vein throm-
bosis gave a history compatible with sural phlebitis. None of the
excretory urograms demonstrated findings suggestive of renal
vein thrombosis, such as enlarged kidney or kidneys, delayed
appearance time and decreased density of contrast medium,
elongated infundibuli, scalloped ureters, or a pear-shaped blad-
der appearance secondary to enlarged collateral channels [25—
271.
Initial laboratory data
Sex and Renal Morpho- Nephrotic Serum Urine
Patient age vein logic duration before creatinine protein
no. years thrombosis stage study, month mg/dl g/24 hr
Follow-
up
month
Most recent laboratory data
Serum Urine
creatinine protein
mg/dl g/24 hr
I M, 25 Bilateral 1 18 1.2 28.0 36 Transplant' Transplant
2 M, 50 Bilateral III 1 1.1 6.5 40 1.4 0.4
4 M, 51 Bilateral III 2 1.2 11.6 27 2.8 10.5
5 M, 59 Bilateral III 8 3.0 23.0 16 Chronic dialysisa 13.0
10 M, 45 Unilateral III 4 1.4 12.5 31 4.0 4.1
II F, 59 Bilateral 11 3 1.2 6.4 38 0.9 0.5
15 F, 63 Unilateral III 4 1.0 5.4 40 0.9 0.9
16 M, 42 Bilateral III 6 1.2 7.1 35 1.2 3.6
17 M, 54 Unilateral II 5 1.1 10.5 39 1.7 10.1
18 M. 44 Unilateral III 6 0.8 5.5 28 1.2 6.1
20 F, 70 Bilateral I 2 1.0 7.1 15 2.5 6.0
22 F, 44 Unilateral III 9 1.0 5.4 23 0.9 0.5
25 M, 47 Bilateral II 1 1.2 11.9 21 1.0 1.4
3 M, 22 Negative III 1 0.8 8.1 44 1.5 9.7
6 F, 66 Negative III 4 1.0 10.2 47 9.0 8.4
7 F, 26 Negative I 1 0.8 3.1 None No follow-up No follow-up
8 M, 53 Negative III 7 2.0 13.5 37 2.1 1.7
9 M, 44 Negative II ? 3.0 14.2 14 Transplanta 14.5
12 M, 28 Negative 1 4 1.9 11.7 2 Death 9.0
13 F, 42 Negative II 4 0.8 11.2 30 1.5 4.2
14 M, 40 Negative III 3 0.9 4.6 33 1.0 5.6
19 F, 52 Negative III 6 1.5 8.3 27 1.1 2.9
21 M, 62 Negative II 1 1.3 12.9 21 1.1 0.5
23 M, 40 Negative III 24 0.9 3.4 25 1.0 2.7
24 M, 72 Negative II 10 1.6 8.4 25 1.8 0.9
26 F, 67 Negative I 1 1.1 4.8 Il 1.1 4.8
27 M, 62 Negative 11 ? 1.2 3.6 27 1.1 0.7
a Serum creatinine level was arbitrarily chosen as 10 mg/dl.
Table 2. Patients with hemostatic surveys
Antithrombin III
Platelets Thrombin Reptilase Fibrinogen
per mm3 time(s) time(s)a mg/dl
degradation Functional Immunologic Factor
products Protamine assay assay VIII
p.g/dI gel % of normal mg/dl % of normal
Patient
no. Angiogram
I Positive
4 Positive
18 Positive
20 Positive
22b Positive
25 Positive
12 Normal
13 Normal
14 Normal
I 55 Normal
19 Normal
21 Normal
23 Normal
27 Normal
Normal
value
534,000 28 20/13 434 40 — 88 22 188
360,000 27 21/14 557 3 Negative 83 29 337
700,000 34 22/14 220 5 -.— — — 268
260,000 31 21/14 776 20 Positive 118 25 326
244,000 30 26/15 1,080 80 Positive 146 — 239
365,000 27 22/15 340 20 Positive 138 — 286
446,000 21 — 516 20 Positive 85 — 175
197,000 37 26/13 756 5 Positive 83 — 337
265,000 22 — 626 2 Negative 95 — 160
295,000 28 19/14 624 2 Negative 100 24 293
388,000 34 25/13 580 5 Positive 97 23 280
205,000 39 30/15 744 3 Positive 102 19 192
340,000 23 18/17 364 3 Negative 97 30 152
435,000 31 20/14 611 20 Negative 63 — 218
100
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C)C
C
a,
C)
E
a,
C),
C,
a)C
C
a)
E
a,
C),
50
The geometric mean of the initial serum creatinine level was
1.2 mg/dl (range, 0.8 to 3.0) in patients with renal vein thrombo-
sis and 1.2 mg/dl (range, 0.8 to 3.0) in patients without renal
vein thrombosis. The average initial 24-hr urine protein excre-
tions of 10.8 gin patients with renal vein thrombosis and 8.5 gin
patients without renal vein thrombosis were not significantly
different. No patient demonstrated qualitative glycosuria on
routine urinalysis.
Coagulation studies. Hemostatic surveys performed in 14
patients (six with renal vein thrombosis) revealed significantly
elevated platelet counts in five patients (two with renal vein
thrombosis) (Table 2). In all but three patients, the plasma
fibrinogen level was at least twice normal. Levels of antithrom-
bin III were depressed in only one patient (one without renal
vein thrombosis). Prothrombin times, partial thromboplastin
times, and activated partial thromboplastin times were normal
in all 14 patients, while factor VIII levels were above normal in
all patients. The thrombin time was prolonged significantly in 12
of 14 patients (six with renal vein thrombosis). In these 12, the
reptilase time was also prolonged. The prolonged thrombin time
could not be attributed to inhibition by fibrinolytic degradation
products because these were elevated in only six patients (four
with renal vein thrombosis). These data suggest that an abnor-
mality of the fibrinogen molecule (prolonged thrombin and
reptilase times) and "hypercoagulability" characterize the clot-
ting alteration observed in association with the nephrotic syn-
drome. Coagulation studies, however, could not differentiate
between patients with and those without renal vein thrombosis.
The observed coagulation abnormalities appear to be reversible
with the disappearance of the nephrotic syndrome, as the
follow-up hemostatic survey was completely normal in three
patients who experienced a nephrotic remission. Unfortunate-
ly, serial coagulation studies could not be performed in every
patient. Such studies might have added insights into the devel-
opment of thromboembolic tendencies, in the chronic nephrotic
state.
Follow-up. Patients were followed-up for an average of 28
months after the renal angiogram study, 30 months for those
with and 26 months for those without renal vein thrombosis. Of
patients with renal vein thrombosis, eight experienced no
change in proteinuria and five experienced a decrease (to < 0.5
g/24 hr in three). Of patients without renal vein thrombosis,
eight showed no change in proteinuria, five showed a decrease
in proteinuria (to < 1 g/24 hr in three), and one was lost to
follow-up. There was essentially no difference between the two
groups as to change in proteinuria over the duration of follow-
up.
In the group of 13 patients with renal vein thrombosis and an
average follow-up time from angiography of 30 months, the
geometric mean of the most recent serum creatinine level was
2.0 mg/dl (Fig. 4). One patient was on chronic hemodialysis,
and a second had received a renal allograft.
Among the 13 patients without renal vein thrombosis who
were available for follow-up, the average observation time was
26 months and the geometric mean of the most recent serum
creatinine determination was 1 .8 mg/dl (Fig. 4). One patient
received an allograft, and one died of sepsis. The rate of renal
function deterioration over the follow-up time did not appear to
be different in the two groups.
During the follow-up observation period, no patient in either
group experienced any thromboembolic complications that
were clinically apparent. The one patient who died, however,
did have bilateral renal vein thrombosis at autopsy; this had
developed during the interim since angiography.
None of the patients in this study received corticosteroids or
immunosuppressant drugs.
Discussion
In the clinical setting of idiopathic membranous glomerulopa-
thy and the nephrotic syndrome, underlying renal vein throm-
bosis can be expected to occur some time during the disease
course in approximately 50% of the patients. The extent of vein
involvement in this study was variable, ranging from that of a
small peripheral venous radical occlusion to partial occlusion of
10 20 30 40
Time, months after initial evaluation
10 20 30 40 50
Time, months after initial evaluation
Fig. 4. Rena/function course. Upper: patients with renal vein thrombo-
sis. Lower: patients without renal vein thrombosis.
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both main renal veins. Interestingly, during the observation of
the 27 patients, none clinically developed an acute main renal
vein thrombosis (commonly characterized by sudden flank pain
and the finding of an enlarged nonfunctioning kidney on excre-
tory urography). Although this type of vein thrombus presenta-
tion may occur with idiopathic membranous glomerulopathy,
our data and those of others [131 indicate that it is rare among
those patients with renal vein thrombosis of any extent. Wheth-
er or not an acute vein occlusion is the culmination of a
progressively occluding main renal vein thrombus is not known,
but most likely it is the consequence of the common coagulation
abnormality that almost all nephrotic patients exhibit and could
represent only a difference in the rate of vein thrombus forma-
tion. Total occlusion of the main renal vein also may occur in
the absence of symptoms if the process is indolent enough to
allow an extensive venous collateral system to develop. How-
ever, the absence of radiographic abnormalities on excretory
urography in our patients, which would suggest extensive
collateral venous circulation development, and the findings of
collateral venous channels at the time of angiography in only
three of 13 patients in our series suggest that occult total main
renal vein occlusion occurs uncommonly.
Various coagulation abnormalities have been described in the
nephrotic syndrome [14—16, 281. These include increased plate-
lets; elevated blood levels of factors V, VIII, and X and of
fibrinogen; depressed antithrombin III levels; accelerated
thromboplastin generation; increased activation of Hageman
factor; and abnormal levels of procoagulant plasma proteins. A
depressed level of antithrombin III, presumably secondary to
urine protein loss, has been suggested as a possible cause of
renal vein thrombus formation and the occurrence of other
thromboembolic phenomena in these patients [17]. Our data do
not support the finding of decreased levels of antithrombin III
but rather suggest that some reversible abnormality of the
fibrinogen molecule develops as a result of the nephrotic
syndrome. Whatever the coagulation abnormality may be, it
does not necessarily seem to predispose patients to renal vein
thrombus formation, however, as no coagulation differences
were noted between patients with and those without renal vein
thrombosis. Whether or not those patients without renal vein
thrombosis at the time of study would eventually develop
thrombus formation is conjectural.
Some studies have included observations that anticoagulation
therapy in nephrotic patients alters the incidence of thrombo-
embolic complications [6, 13, 221. The absence of anticoagulant
therapy in all of our patients without renal vein thrombosis
seemed to have no deterimental effect in this regard, as none of
the patients experienced a recognized thromboembolic event
during the period of observation—a difference that we cannot
explain. The use of anticoagulants, however, was associated
with the resolution and disappearance of renal vein thrombus in
three patients, but the resultant effect on the course of renal
function and proteinuria in these patients was not significant.
Does the development of thrombus formation in the renal
venous system influence proteinuria or the renal function
course? In the absence of an acute renal vein occlusion,
thrombus formation of any other degree would seem to bear no
influence on these two clinical parameters. Proteinuria is nei-
ther caused nor aggravated by the presence of renal venous
thrombi. This finding is in agreement with Llach, Papper, and
Massry [131. Although the number of patients in this study is
small and the period of observation relatively short in a disease
with an indolent prolonged course [17, 29—311, renal venous
thrombus formation was not associated with a more rapid renal
function deterioration in patients receiving anticoagulants for a
minimum of 1 year. Whether or not a more rapid course of renal
function deterioration would have occurred in the absence of
anticoagulant use cannot be answered by this study.
Diagnostic studies used for the detection of renal vein throm-
bosis are invasive procedures associated with some risk, and
they are expensive. We conclude from our data that the search
for renal vein thrombosis in nephrotic patients using presently
available techniques is not without hazard. And until further
information is available, routine angiographic assessment of the
renal veins in this situation is not considered an essential part of
the evaluation until a controlled group of patients not treated
with anticoagulation therapy can be compared with a treatment
group. An exception to this, however, would be the patient with
rapidly deteriorating renal function in whom complete main
renal vein thrombus formation in rare instances could be a
contributing and reversible influence.
An argument for the use of anticoagulant therapy seems
supportable in a negative sense from our experience. Since
coagulation abnormalities in nephrotic patients may quite likely
be in part responsible for thromboembolic phenomena and
because these abnormalities are persistent unless the nephrotic
syndrome disappears, there exists a cogent rationale for the
chronic use of anticoagulant treatment in those patients who do
not experience a nephrotic remission, if only for the purpose of
preventing thromboemboli. In addition, renal vein thrombus
formation, even if it resolves, may recur if nephrosis persists
[321. The risk of anticoagulation therapy for a prolonged period,
therefore, must be balanced against the incidence and serious-
ness of these thromboembolic events and the possibility of
recurrent renal vein thrombosis.
Prophylactic anticoagulation against the possible develop-
ment of an acute and complete renal vein thrombosis, however,
does not seem to be warranted because of its uncommon
occurrence and the favorable outcome of this complication with
the use of anticoagulation at the time of clinical recognition, as
reported by several investigators [32—34].
Reprint requests to Dr. R. D. Wagoner, Mayo Clinic, Rochester,
Minnesota 55905, USA
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